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Abstract
Sexually transmitted diseases (STD) are among the most common infections worldwide. 
These bacterial infections have spread predominantly in the developing/underdeveloped 
countries, the most common being syphilis, gonorrhea and those induced by Chlamydia 
trachomatis, Ureaplasma urealyticum or Mycoplasma spp. Due to extensive usage of antibi-
otics in the recent past, these bacteria developed resistance to those commonly used for 
treatment, such resistant strains becoming a public health problem in a number of coun-
tries. It is well documented that bacterial STD agents are difficult to detect using standard 
culture media because these methods require special conditions and adequate nutrients. 
Antimicrobial susceptibility testing is, therefore, difficult to obtain in such cases. In recent 
years, genetic tests have been frequently employed in STD diagnosis. The study of genes 
that induce resistance to antibiotics using DNA isolated from these bacteria may prove 
to be a viable alternative. Genetic methods enable the DNA extraction from different bio-
logical samples, and both the presence of the bacteria and their resistance to one or more 
antibiotics can be determined from a single DNA sample. By studying the genes that 
induce antibiotic resistance and the plasmids that transfer such genes, the mechanism 
that leads to antibiotic resistance can be elucidated.
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1. Introduction
Sexually transmitted diseases (STD) are caused by a wide variety of bacteria, viruses or par-
asites transferred from one human being to another primarily by vaginal, anal or oral sexual 
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contact. Different STD can coexist or be simultaneously transmitted, the presence of any such 
infection increasing the risk of contracting other STD types. Prolonged, untreated infections 
with these pathogens can induce anexitis, endometritis, pelvic peritonitis or spontaneous 
abortions (in women) and urethritis, prostatitis or epididymitis (in men), respectively.
Reasons for STDs’ recurrence in some sexually active women include the anatomy of the 
female sex, multiple partners or nonusage of condoms [1]. Such infections present an increas-
ingly serious threat to global public health, especially for mothers or babies, causing severe 
complications such as cancer of the cervix, spontaneous abortions, premature births, low birth 
weight or infertility [2]. A number of studies concluded that ulcerative and nonulcerative 
STDs significantly increase HIV transmission, and drug resistance is complicating the fight 
against HIV [3]. The presence in the genital tract of such microbial pathogens may be due to 
a poor hygiene or risky behaviors as mentioned above [4].
Microorganisms make use of a wide range of mechanisms to resist to antibiotics and survive 
their attack. The emergence of antibiotic resistance is a natural biological phenomenon that 
occurs as a reaction to the use of antibiotics. Antibiotic resistance results from the bacteria ability 
to resist to antibiotics as they develop and multiply in media with high antibiotic concentration.
The main causes of antibiotic resistance are their abusive usage and the spread of resistant 
bacterial strains or genes bearing information able to induce resistance. There are multiple 
mechanisms leading to antibiotic resistance, one involving resistance plasmids carrying genes 
responsible for resistance to antibiotics [5, 6]. The phenomenon of antibiotic resistance can 
also develop via mutations or by acquiring resistance genes from other resistant bacteria [7–9].
Resistance to macrolides observed in the STD strains is often associated with mutations in the 
ribosomal protein genes [10, 11]. It is assumed that mutations in a specific region of the 23S 
rRNA play a major role in inducing resistance to macrolides as a result of their interaction 
with the ribosomes [12, 13].
Treatment failure because of bacterial resistance to the major groups of antibiotics as a result 
of extensive usage became a serious threat to human health. Increased usage of nucleic acid 
amplification tests (NAATs) in the diagnosis of STD leads to the elimination of culture-based 
techniques, depleting the number of live strains available for resistance testing. A lack of rou-
tine test-of-cure makes it impossible to distinguish treatment failure from reinfection [14]. 
The cost of health care for patients with resistant infections is higher due to longer duration of 
illness, additional tests and use of more expensive drugs.
It is obvious that the microorganisms’ antimicrobial resistance is a dynamic phenomenon 
which points out the need for updated prevalence and susceptibility data from vast geo-
graphic areas being available for relevant institutions [4].
2. Most common bacterial STD agents and their resistance to antibiotics
STD infections are induced by a diversity of bacterial pathoges, including Neisseria gonorrhoeae, 
Mycoplasma hominis, Mycoplasma genitalium and Ureaplasma urealyticum. However, Chlamydia 
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trachomatis is the leading cause of sexually transmitted bacterial infections worldwide and, in 
developing countries, the leading cause of preventable blindness [15].
C. trachomatis strains are obligate intracellular bacteria presenting a unique biphasic develop-
mental cycle. Following the endocytosis of the small infectious bodies into the host cell and 
their inclusion into specialized vesicles, C. trachomatis strains differentiate into metabolically 
active reticular bodies and replicate until the inclusion fills the host cell. At this stage, the 
reticular bodies differentiate into elementary bodies and are being released from the cell to 
continue the infection [14].
Infection further leads to diseases such as cervicitis, pelvic inflammatory disease, urethritis, 
proctitis, lymphogranuloma venereum, trachoma or reactive arthritis. Transmission of STD 
pathoges is largely uncontrolled as over 70% of the women and 50% of the men infected with 
C. trachomatis are asymptomatic. “Silent” chronic infection has been recognized as a signifi-
cant cause of infertility in women. Symptomatic individuals seeking medical care often do not 
benefit from tests for initial diagnosis or cure, largely due to inherent costs. Empirical antibi-
otics treatment is hastening the development of drug resistance, as has already occurred for a 
closely related species, Chlamydia suis, in which a tetracycline transposon was acquired from 
another pathogens residing in the guts of pigs [16].
C. trachomatis is a Gram-negative parasite causing a wide range of inflammations in the uro-
genital tract. Clinical isolates exhibiting resistance to azithromycin and associated with recurrent 
infections have been described previously [17]. While several reports of human chlamydial infec-
tions that do not respond to tetracycline or doxycycline were produced, no human pathogenic 
chlamydial strains that demonstrate stable tetracycline resistance have yet been isolated [17, 18].
Plasmids are small circular self-replicating DNA particles coexisting in the bacterial cells that 
are capable of exporting genetic information from the bacterial chromosome. They can trans-
fer genes usually not present in the bacterial chromosome. In prokaryotic organisms, plasmids 
usually code for genes that facilitate survival of the bacteria in the environment. In chlamydia, 
apart from their participation in glycogen synthesis and encoding proteins responsible for their 
virulence, their role has yet to be clearly recognized. Resistance plasmids carry genes responsible 
for antibiotics resistance. Plasmids and bacteriophages can be employed in the diagnostics of 
chlamydioses. Plasmids are already used for detection of chlamydial infections. Bacteriophages 
could be used as therapeutic agents, potentially replacing antibiotics to address the increasing 
problem of antibiotic resistance among chlamydia. The easy transfer of infectious elementary 
bodies into other cells can prove to be a useful biotechnological tool in the treatment of chla-
mydioses, particularly in the case of concealed and latent infections, principally at the time of 
chlamydial resistance to antibiotics used by choice of treatment (tetracyclines) [5]. According 
to some authors, chlamydial plasmids are not conjugative plasmids, and they do not code anti-
biotic resistance and do not share the capacity for integration, except for the integrative plas-
mid revealed in C. suis, which is integrated in a genomic island together with some insertion 
sequences in the bacterial chromosome that encodes genes of resistance to tetracycline (tetC) [16].
Chlamydial infections have high recurrence rates among sexually active populations [19]. 
However, whether this recurrence rate for the disease is due to reinfection or to persistent 
infection with the same organism has been difficult to determine [20]. Immunity to  chlamydial 
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infections is type specific; once the initial infection was resolved, reinfection is believed to 
result from exposure to chlamydial strains differing in type from the initial infecting strain [21]. 
In contrast, persistent infections are considered those in which Chlamydia has entered a non-
infectious state that is metabolically quiescent.
Chlamydial infections are very likely to recur even when appropriate drug therapy is in place. 
Most clinical failures occur due to reinfection or relapse as the bacterial phenotype deviates 
to persistent, non replicating antibiotic-resistant types able to revert to the typical reticulate 
body phenotype once treatment is complete [22, 23]. Administration of tetracyclines and 
macrolides, impeding bacterial translation by binding to the 30S or 50S ribosomal subunits, 
is viewed as the recommended first-line therapeutic regimen for chlamydial infections [24]. 
Clinical isolates from patients with recurrent C. trachomatis infection were documented to 
have significant resistance against macrolides [25, 7].
Other frequently diagnosed STD worldwide is gonorrhoea, exhibiting a recent rise in its 
global incidence. N. gonorrhoeae are Gram-negative facultative intracellular bacteria account-
ing for about three-quarters of urethral discharge cases among South Africa men presenting 
to primary healthcare clinics [8]. Chlamydia and gonorrhoea share several aspects of their dis-
ease outcomes, both being able to cause pelvic inflammatory disease and epithelial scarring 
which can lead to infertility. On the other hand, they can also be asymptomatic. However, 
 N. gonorrhoeae infections tend to be more acute, with symptoms including purulent discharge 
and acute local inflammation. Rashes and septic arthritis may occur if the bacterium dissemi-
nates through the host [14].
While not required for individual patient management, laboratory investigations are instru-
mental in the choice of antimicrobial agents. Due to a high prevalence of fluoroquinolone-
resistant N. gonorrhoeae strains observed in the last decade, first-line therapy was changed to 
single-dose oral cefixime. However, ciprofloxacin—the first line treatment option until about 
2008—is still recommended for the treatment of presumptive gonorrhoea in patients with a 
history of severe allergy to cephalosporins. The increasing prevalence of N. gonorrhoeae anti-
microbial resistance has become a global public health problem as lesser abilities to develop 
N. gonorrhoeae cultures and to perform antimicrobial susceptibility testing make monitoring 
antimicrobial resistance rather difficult. A significant advantage to public health programs 
and selective patient management could be provided by the use of molecular assays for gono-
coccal antimicrobial resistance, particularly in the case of fluoroquinolones [8].
Resistance to all antimicrobial agents has developed in some N. gonorrhoeae strains. The global 
spread of multidrug-resistant N. gonorrhoeae is a growing concern, clinical treatment failures 
with the extended-spectrum cephalosporins (the last option for empirical first-line monother-
apy) being recently reported. In many countries, dual antimicrobial therapy (ceftriaxone plus 
azithromycin) is the recommended first-line empirical treatment [9].
Mycoplasmas, the smallest free-living microorganisms, are another important source of STDs. 
They belong to the class of Mollicutes and were first described in the 1950s, following isolation 
from a male patient with nongonococcal urethritis [26]. In healthy sexually-active adults uro-
genital, mycoplasmas are part of the normal commensal flora of the genital tract. M. hominis 
Antibacterial Agents112
and U. urealyticum are involved in a wide array of infectious diseases, in adults as well as in 
children. They are suspected of being the causative agents of nongonococcal urethritis, pre-
natal infections leading to pregnancy complications, infertility, bacterial vaginosis and pelvic 
inflammatory disease [27].
In contrast to other bacteria, Mycoplasma spp. and Ureaplasma spp. are not susceptible to peni-
cillins, cephalosporins, vancomycin or rifampicin. Present data suggest that urogenital myco-
plasmas are susceptible to agents interfering with protein synthesis, such as the tetracyclines, 
macrolides, aminoglycosides and chloramphenicol, but also to topoisomerase inhibitors such 
as the fluoroquinolones. Various mycoplasmal species may pose selective innate resistance 
to an antibiotic to which other species might be sensitive, for example, all M. hominis strains 
are resistant to erythromycin. Mycoplasma also can develop resistance to antibiotics to which 
they are usually considered sensitive [28].
As a major cause of nongonococcal urethritis in men, having been directly linked to cervicitis, 
endometritis, and pelvic inflammatory disease in women, M. genitalium holds a distinct posi-
tion in the spectrum of emerging pathogenic bacteria for humans. It has been isolated from the 
respiratory tracts and synovial fluid of diseased individuals along with the human pathogen 
Mycoplasma pneumoniae [29–31]. M. genitalium is also the smallest known self-replicating cell, 
with a genome size of only 580 kb, an aspect which imposes severe biosynthetic limitations [32].
Because of extreme difficulties in cultivating M. genitalium, many researchers have relied 
on the results of serological and polymerase chain reaction (PCR) assays to establish links 
between M. genitalium and human disease. Antimicrobial susceptibility testing is conse-
quently rather difficult.
Various investigators noted that resistance to tetracyclines of the mycoplasmas’ is on an uphill 
trend worldwide [33], a Tunisian study reporting resistance rates of 22.7 and 25% among 
ureaplasmas and M. hominis, respectively [34]. Even higher values (45%) were reflected in 
an American study, in contrast to some European ones suggesting much lower figures [35]. 
Macrolides and lincosamides are the antibiotics widely used for U. urealyticum infections, 
especially among children and patients allergic to tetracyclines or quinolones. However, wide-
spread macrolide resistance in U. urealyticum has been recently reported. In contrast, pris-
tinamycin, a newly promoted macrolide, proved to be ineffective against U. urealyticum and 
M. hominis [36]. Still, for sensible patients, for example, premature neonates, one must carefully 
consider the potential toxicity of the antibiotics in attempting to remove such bacteria [37].
3. Determining the antibiotics resistance of pathogen STD agents
Although resistance to several antibiotics has been reported in vitro, no evidence that C. tracho-
matis—generally treated with a single dose of azithromycin—has developed such resistance 
were documented [38]. For both chlamydia and syphilis, no internationally agreed methods to 
assess minimum inhibitory concentrations (MIC) in vitro are standardized [39]. Consequently, 
assessment of antibiotic resistance relies but on the identification of treatment failures.
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The emergence of drug resistance in many pathogenic bacteria compromised severely the 
therapeutic utility of macrolides. The occurrence of macrolide resistance is yet undocumented 
for many bacterial pathogens. The various molecular mechanisms inducing bacterial resis-
tance can be collectively characterized as involving drug efflux, drug inactivation or altera-
tions in the drug target site. The probability of developing resistance depends on the types and 
quantities of drug to which these organisms are exposed [10]. For instance, shortly after eryth-
romycin was introduced in therapy in the 1950s not only was resistance in bacterial patho-
gens observed, but erythromycin-resistant strains were found to be cross-resistant to all other 
macrolides and also to the chemically unrelated lincosamide and streptogramin B drugs [40].
Resistance to macrolides of the C. trachomatis strains is often associated with mutations in the 
ribosomal protein genes, particularly in L4 and L22, but also as well as with mutations in the 
peptidyl transferase region of domain V of the 23S rRNA gene. The later region was demon-
strated to play an important role in the interaction of the ribosome with macrolides [10, 11]. 
Studies on macrolide-resistant C. trachomatis clinical isolates led to the first finding of muta-
tions in the peptidyl transferase region of the 23S rRNA gene [12].
Many strains of C. suis, a pathogen of pigs, express a stable tetracycline resistance phenotype. 
This resistance pattern was demonstrated to be associated with a resistance gene, tet(C), in the 
chlamydial chromosome. In tetracycline-resistant C. suis strains, four-related genomic islands 
sharing significant nucleotide sequence identity with resistance plasmids carried by a variety 
of bacterial species were identified. These genomic islands provided the first examples of 
horizontally acquired DNA integrated into a natural isolate of chlamydiae [16].
Lateral gene transfer (LGT) is a means allowing C. trachomatis to generate variants of enhanced 
relative fitness, as suggested by the high frequency of between-strain genetic recombinants of 
C. trachomatis among isolates obtained from human STD. Although hampered by the devel-
opment of the pathogen, experimental investigations on this phenomenon detected in vitro 
LGT between strains of C. trachomatis in vitro. Host cells were simultaneously infected with an 
ofloxacin-resistant (Ofxr) mutant of a serovar L1 strain and a rifampin-resistant (Rif r) mutant 
of a serovar D strain. DNA sequencing was used to map genetic crossovers. Development 
occurred in the absence of antibiotics, the progeny being subjected to selection for Ofx r Rif r 
recombinants. Natural DNA transformation is a plausible mechanism, although trans-DNA 
lengths were previously associated only with conjugation in known microbial LGT systems 
[41]. Nowadays, LGT studies can be performed with various other C. trachomatis combina-
tions to study the mechanisms by which these strains can transfer resistance genes.
As for C. trachomatis no reliable laboratory-based gene transfer system was available, in vitro 
generation of recombinants from antibiotic-resistant strains was used to study the LGT, 
essential for generating between-strain genomic recombinants of C. trachomatis able to facil-
itate the organism’s evolution [42]. For 16 in vitro-derived recombinants of ofloxacin- and 
rifampin-resistant L1 and D strains, multiple loci were examined and compared with the same 
sequenced loci among 11 clinical recombinants. Phylogenetics and bioinformatics were used 
in examining breakpoints and recombination frequency. Without any misclassification, in 
vitro and clinical isolates clustered perfectly into two groups using Ward’s minimum variance 
based on breakpoint data. gyrA (confering ofloxacin resistance) and rpoB (confering rifampin 
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resistance), but trpA as well, presented significantly more breakpoints among in vitro recom-
binants than among clinical recombinants. Significant selections were evidenced at other loci 
as well, results indicating that the in vitro model is statistically different from any natural 
recombination events. Additional genomic studies to determine the responsible factors for 
selection biases at unexpected loci are needed to clarify whether these are important for LGT 
approaches in the genetical manipulation of C. trachomatis [42].
Several genetic mechanisms are employed by pathogenic microbes for producing variants to 
counter host defenses. Such a high proportion of urogenital tract isolates presenting amino 
acid substitutions in the polymorphic ompA gene which encodes the major outer membrane 
protein (MOMP) suggests a role for spontaneous mutation followed by in vivo selection in the 
bacteria’s route to avoid human immune defenses [43, 44]. Humans have diverse B and T cell-
mediated responses to MOMP, the occurrence of mutations in the same ompA segments of 
multiple clinical isolates suggesting the protectiveness of at least some of these responses [45]. 
Evidences also indicate that in vitro LGT may contribute significantly to the origin of 
enhanced-fitness variants in C. trachomatis [41]. The LGT mechanism has not been identified, 
but various publications investigating possible relationships between in vitro LGT and the 
high frequency of LGT recombinants in clinical isolates [46] suggested that a certain percent-
age of the many millions of clinical infections involve more than one strain of C. trachomatis. 
However, a recent study failed to identify mutations in the 23S rRNA genes of resistant 
mutants selected following enrichment by serial passage in the presence of subinhibitory con-
centrations of azithromycin [47].
Investigating mutations in the 23S rRNA gene of macrolide-resistant isolates of wild-type 
C. trachomatis obtained from clinical samples and mutant strains selected using subinhibitory 
concentrations of the macrolides were the objective of another recent study [13] in which a 
set of resistant clinical isolates of C. trachomatis obtained from patients attending the Tianjin 
Institute of Venerology (Tianjin, China) during 2005 2008 was differentiated into wild-type 
and mutant strains, the 23S rRNA mutations in the isolates then being identified. Each patient 
was sampled for only one isolate, the antimicrobial agents examined being erythromycin, 
azithromycin and josamycin. The in vitro MICs of antibiotics in the isolated clinical strains 
of C. trachomatis were determined. As the MIC values of erythromycin in the eight strains of 
C. trachomatis were higher than the in-blood erythromycin concentration (1 μg/ml) and even 
higher than the tissue concentration of erythromycin in the urogenital system, these were 
considered to be wild-type macrolide-resistant strains of C. trachomatis.
Following PCR amplification of the 23S rRNA gene of the eight wild-type resistant isolates 
(exhibiting MIC values above the tissue concentration of the antibiotic present in the uro-
genital system), no resistance-associated mutations were found at 2057 (E. Coli numbering 
scheme), 2058 or 2059, while only three resistant isolates presented the T2611C mutation. The 
isolates included the T2611C mutation in the case of two patients with persistent infection, 
but no mutations were found at 2058. A2057G mutations were found in six mutant isolates, 
while T2611C mutations were found in 10 mutant isolates. Two mutant resistant isolates 
presented A2059G mutations, while two of the resistant isolates exhibited no mutations in 
their 23S rRNA sequences. Medical records indicated no response to azithromycin on behalf 
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of the patients infected with mutant strains. The sensitivity of the wild-type clinical iso-
lates to erythromycin and azithromycin was found to be lower than previously reported [7], 
explaining the high recurrence rate and treatment failure reported for chlamydial infections. 
Azithromycin treatment was unsuccessful in eight resistant strains. The wild-type resistant 
strains presented no mutations in the 23S rRNA, suggesting that other molecular mecha-
nisms were responsible for their resistance. Possible mechanisms underlying drug resistance 
should be investigated in the future in order to understand the resistance of isolates exhibit-
ing no mutation in the peptidyl transferase region of the 23S rRNA gene. The merits of the 
Chinese study are that, for the first time, wild-type macrolide-resistant C. trachomatis strains 
have been observed in vitro, and for the first time, A2057G and A2059G mutations in the 
peptidyl transferase region of the 23S rRNA gene have been found in C. trachomatis with 
selective macrolide resistance [13].
While certain other studies reported that mutations observed in clinical strains were also 
found in laboratory strains, the reverse was found not to be true likely because rRNA muta-
tions leading to drug resistance in a clinical pathogen often become apparent only when a 
drug therapy fails to eradicate that pathogen [10].
The first reported cases of clinically significant C. trachomatis infection resistant to ofloxa-
cin and azithromycin came from a case study of two patients with C. trachomatis infections 
demonstrating multidrug resistance as they persisted after standard treatment [17]. A com-
mercially available PCR test (Amplicor PCR; Roche Diagnostics, Indianapolis) was employed 
to detect C. trachomatis in urine and urethral/cervical swab specimens. Antimicrobial suscep-
tibility testing on C. trachomatis strains isolated from cultured cells originating from urethral/
cervical swab specimens was conducted for doxycycline, azithromycin and ofloxacin. In vitro 
antimicrobial susceptibility testing was also completed.
The MIC (antibiotic concentration level where fluorescent antibody staining failed to high-
light typical inclusions after incubation in cell culture) and the minimum chlamydicidal 
concentration allowing no inclusions on passage in an antibiotic-free medium (MCC) 
of these antimicrobial agents for these isolates were determined after a subsequent pas-
sage of the contents of duplicate unstained wells to a fresh monolayer in antibiotic-free 
medium. C. trachomatis DNA samples prepared from endocervical or urethral swab speci-
mens were amplified by a nested PCR assay, amplicons being purified with a PCR purifi-
cation kit (Qiagen, Chatsworth, CA). Sequencing was conducted on a model 377 (Perkin 
Elmer Biosystems, Foster City, CA) automated sequencer using a dRhodamine Terminator 
Cycle Sequencing kit according to the manufacturer’s instructions. Edited sequences were 
aligned and analyzed with the GCG (Genetic Computer Group, Madison, WI) software 
package. Genotypes were determined by comparison of resulting sequences with refer-
ence C. trachomatis omp1 sequences in the GenBank database. Conclusions were that the 
mechanism responsible for heterotypic resistance in C. trachomatis remains unknown, being 
possible that the observed multidrug resistance to be phenotypic rather than genotypic in 
nature since the molecular targets of azithromycin, doxycycline and ofloxacin are quite dif-
ferent, and it is highly unlikely that a single or a limited number of gene mutation(s) could 
be responsible for simultaneous resistance to these diverse agents [13, 48].
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Fosfomycin is a broad-spectrum antibiotic that irreversibly binds to the active site of murA. 
Fosfomycin renders the enzyme inactive by forming a covalent adduct with a cysteine resi-
due in the active murA site [49]. It was demonstrated [50] that C. trachomatis can be resistant 
to high concentrations of fosfomycin. The genome sequences of C. trachomatis contain gene 
homologues in the peptidoglycan (PG) biosynthesis pathway, including murA. The study 
aimed to demonstrate in vitro activity of Chlamydia murA and in vivo activity in E. coli and to 
determine whether murA mRNA was expressed in Chlamydia bacteria at any time during the 
chlamydial developmental cycle. The murA gene from C. trachomatis serovar L2 was cloned 
and placed under the control of the arabinose-inducible, glucose-repressible ara promoter 
and transformed into Escherichia coli. Findings were that the expression of C. trachomatis murA 
mRNA is cell cycle dependent. Collectively, the data support the notion that Chlamydia organ-
isms contain PG and suggest that PG in Chlamydia plays a role in development and division. 
Elucidating the existence of PG in Chlamydia spp. is significant for the development of novel 
antibiotics targeting the chlamydial cell wall.
Another study [51] made use of antibiotic resistance assays and whole genome sequencing to 
interrogate the hypothesis that two clinical isolates (IU824 and IU888) have acquired certain 
antibiotic resistance mechanisms (tetracycline efflux mediated by the presence of one of the 28 
genes, ribosomal protection via carriage of one of the 10 tet genes or one otr gene, enzymatic 
inactivation conferred by one of the three tet genes or mutations in the 16S rRNA gene—
identified as lending tetracycline resistance). The genes conferring the first three resistance 
mechanisms reside in plasmids and insertion elements (horizontally transmissible elements 
enabling their transfer among a wide range of bacterial species). No tetracycline resistance was 
evidenced in the two investigated strains, comparisons of the genome and plasmid sequences 
failing to identify regions able to accommodate horizontally acquired resistance genes.
Inability to introduce stably maintained DNA and perform targeted gene manipulation are 
long-standing limitations slowing progresses in understanding many of the components 
associated with the basic biology and pathogenesis of Chlamydia. One of these limitations was 
removed when a novel method for introducing DNA and modificating the native plasmid to 
allow effective selection of transformants has enabled the development of key molecular tools 
for studying Chlamydia. This transformation system was employed to test the expression of 
a diverse set of fluorescent proteins and to demonstrate the utility of subcellular localization 
studies [52]. The C. trachomatis developmental cycle incorporates numerous poorly under-
stood processes, but a method for transforming Chlamydia has recently enabled the devel-
opment of essential molecular tools to better study the biology and pathogenesis of these 
bacteria. Evaluation of green fluorescent protein (GFP) expression demonstrated a tight con-
trol of gene regulation by the Tetracycline repressor and anhydrotetracycline. Sensible GFP 
induction was observed in mid stages of the developmental cycle, data suggesting that meta-
bolic diversity is affecting induction and/or expression during later stages [53].
Previously expensive, laborious and largely inaccessible, routine identification of tetracycline 
resistance loci became possible through the high-throughput whole-genome sequencing tech-
nology that emerged in recent years and enabled the low-cost interrogation of a large number 
of C. trachomatis genomes [54].
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N. gonorrhoeae has quite a history in acquiring or developing resistance to antibiotics, includ-
ing all first-line treatment drugs such as sulphonamides, penicillins, tetracyclines, macrolides, 
fluoroquinolones or, more recently, cephalosporins. Mechanisms for N. gonorrhoeae resistance 
to antibiotics may involve efflux systems, mutations in the chromosomal targets or acquisition 
of novel genes by transformation or plasmid-mediated conjugation. Chromosomal mosaic 
penA genes have been recently identified to confer resistance to extended-spectrum cephalo-
sporins including ceftriaxone and cefixime, posing serious threats regarding the development 
of an untreatable ‘superbug’ [55].
In bacteria with multiple rRNA (rrn) operons, the effect of a beneficial mutation in one operon 
is likely to be diluted out, thus offering no significant phenotypic advantage. However, ampli-
fication of a mutant allele could confer a resistant phenotype, as it occupies the majority of 
the bacterium’s rrn operons. While implementation of both of these latter systems requires 
the acquisition of exogenous genetic material, moderate levels of macrolide resistance have 
been observed in N. gonorrhoeae upon overexpression of an endogenous membrane transport 
system. The potential risks of resistance developing via modification of endogenous efflux 
systems such as mtrRCDE of N. gonorrhoeae or via drug inactivation remain to be assessed [56].
A wide range of plasmids, from the small 4.2 kb plasmid to larger conjugative plasmids pro-
moting their own transfer between strains and carrying determinants of antibiotic resistance, 
is associated with N. gonorrhoeae strains [6].
The use of molecular assays for gonococcal antimicrobial resistance surveillance is particu-
larly suited to the fluoroquinolones, where mutations occur at defined bases in the quinolone 
resistance-determining regions (QRDRs) of the N. gonorrhoeae gyrA and parC genes. A real-
time PCR (RT-PCR) assay was modified to allow the simultaneous detection of N.gonorrhoeae 
and quantification of the gonococcal susceptibility to ciprofloxacin using clinical samples, 
the assay being validated with the use of DNA extracted from 40 linked isolates and urethral 
swabs. The 40 isolates consisted of 11 susceptible isolates, 2 isolates of intermediate suscep-
tibility and 27 resistant isolates. Twenty-four of these linked first-pass urine samples were 
obtained from men presenting with urethral gonorrhoea [8]. Each gonococcal isolate in the 
study was reidentified based on Gram staining—a positive oxidase test (Davies Diagnostics, 
Randburg, South Africa) and coagglutination with the Phadebact® Monoclonal Antibody 
Test (Pharmacia Diagnostics AB, Uppsala, Sweden). Ciprofloxacin-susceptibility profiles 
were confirmed using Etest-based MIC assays, while ciprofloxacin susceptibility phenotypes 
were determined according to Clinical and Laboratory Standards Institute (CLSI) guidelines.
DNA was extracted from an additional 33 first-pass urine specimens collected from patients. 
A previously published RT-PCR assay differentiating ciprofloxacin susceptible from non-
susceptible N. gonorrhoeae was modified by inclusion of primers and a probe to detect the 
gonococcal cytosine-specific DNA methyltransferase gene (dcmH) as a positive control tar-
get. To generate gyrA and parC QRDR products for sequencing, amplification of the required 
sequences was undertaken using isolate-derived DNA. The RT-PCR assay correctly predicted 
that 15/33 samples were associated with ciprofloxacin-susceptible gonorrhoea, as both gyrA 
and parC amplicons were produced. The 18 samples in which gyrA amplicons were not gener-
ated were correctly predicted to come from patients with gonorrhoea either of intermediate 
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susceptibility or resistant to ciprofloxacin. The 18/33 samples that produced parC amplicons 
came from 15 patients with ciprofloxacin-susceptible gonorrhoea, 2 patients infected by 
N. gonorrhoeae isolates with intermediate susceptibility to ciprofloxacin and 1 patient with cip-
rofloxacin-resistant gonorrhoea. DNA extracted from first-pass urine of 15 out of 16 patients 
with ciprofloxacin-resistant gonorrhoea generated no gyrA and parC amplicons. The modi-
fied RT-PCR assay previously described in this paper offered a faster method for combined 
N. gonorrhoeae diagnosis and determination of ciprofloxacin susceptibility than traditional 
culture and antimicrobial resistance testing [8].
As infection with Neisseria gonorrhoeae is one of the major causes of STDs in Romania, we con-
ducted a study on bacterial gyrA and parC genes to determine the presence of ciprofloxacin-
resistant N. gonorrhoeae strains. About 200 subjects from Cluj-Napoca (Romania) suspected 
of STD infections were enrolled in our study. DNA extracted from first void urine samples 
was purified and amplified via multiplex PCR for the simultaneous detection of 6 STDs: 
Trichomonas vaginalis, M. hominis, M. genitalium, C. trachomatis, N. gonorrhoeae and U. urealyti-
cum. DNA obtained from N. gonorrhoeae positive samples was amplified using gyrA, parC and 
N. gonorrhoeae-specific dcmH gene primers designed using a modified version of previously 
published sequences [8]. DNA from a N. gonorrhoeae ATCC 49226 strain (sensible to ciprofloxa-
cin) served as positive control. The amplicons were separated via gel electrophoresis (Figure 1).
Figure 1. GyrA, parC and dcmH genes—agarose gel electrophoresis. NC: negative control, S1–S3: samples, PC: positive 
control.
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The dcmH gene was amplified in all of the samples collected from the 15 (7.5%) patients 
diagnosed with gonorrhea, confirming the accuracy of both PCR methods employed in the 
study. The gyrA and parC genes were amplified in eight samples accounting for ciprofloxacin- 
sensitive strains (e.g., Sample S3 in Figure 1). The two genes were also present in the positive 
control sensitive to ciprofloxacin, proving that the primers were correctly designed. The gyrA 
gene was not amplified in six samples presenting only the parC and dcmH genes, that is, con-
stituting intermediate-resistant strains (e.g., Sample S1 in Figure 1). One sample (Sample S2 in 
Figure 1) generated neither gyrA nor parC amplicons, signifying that the strain was resistant 
to ciprofloxacin.
This was the first Romanian study on STD pathogens demonstrating the presence of genes 
providing antibiotic resistance in the N. gonorrhoeae strains. The study confirmed the presence 
of N. gonorrhoeae strains resistant to ciprofloxacin in Romania. Most of the strains detected 
were intermediate-resistant ones.
Elsewhere, mutations at various genes such as 23S rRNA, mtrR and penA (encoding penicil-
lin-binding protein 2, PB P2) have been identified to associate with chromosomally medi-
ated resistance to azithromycin (AZM) [57] and extended-spectrum cephalosporins [58] in 
 N. gonorrhoeae.
A Chinese study combined antimicrobial susceptibility determinations with molecular-
based analysis of AZM-resistant in N. gonorrhoeae according to the WHO recommendations. 
Bacterial genome DNA was extracted from each AZM-resistant isolate identified, mutations 
in the four alleles of the 23S rRNA, mtrR and penA genes, as well as polymorphisms in porB 
and tbpB, being amplified [59, 60].
A high potential for macrolide resistance to occur by mutations in the 23S rRNAs of the bac-
teria was predicted. The target site for macrolides is the large (50S) subunit of the bacterial 
ribosome. Many cases of macrolide resistance in clinical strains can be linked to the alteration 
of specific nucleotides in 23S rRNA within the large ribosomal subunit [10]. Findings were 
that single base substitutions in rRNA provide macrolide resistance [61].
About 2000 women were tested for vaginal infections. About 1536 of the 2000 vaginal swab 
samples cultivated in the study [4] were infected with at least one microorganism, a positivity 
rate of 76.80%. M. hominis and U. urealyticum combined accounted for <7%. The antimicrobial 
tests were conducted on Muller agar medium, and antimicrobial activities were evaluated by 
measuring the diameters of inhibition around the disks. M. hominis strains were found to be 
more resistant than those of U. urealyticum.
In a 65-month study conducted on 373 patients attending the Clinic of Dermatovenereology 
in Belgrade from January 2007 to May 2012, urethral and cervical swabs were analyzed for the 
presence of U. urealyticum and M. hominis. About 48 (12.9%) of the 373 specimens tested were 
positive for urogenital mycoplasmas: 37 (77.8%) were found to be positive for U. urealyticum 
and 6 (22.9%) for M. hominis, while 5 (10.4%) were positive for both. The test also provided 
information regarding the density of each organism and its susceptibility to doxycycline, josa-
mycin, ofloxacin, erythromycin, tetracycline, ciprofloxacin, azithromycin, clarithromycin and 
pristinamycin [62, 63].
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Among the 37 isolates of U. urealyticum, 34 (94.6%) were sensitive to doxycycline. Furthermore, 
josamycin and azithromycin (70.3 and 67.6%, respectively) were found to be highly and mod-
erately potent against U. urealyticum. M. hominis was sensitive to doxycycline (83.3%) and 
moderately sensitive to ofloxacin (66.7%). M. hominis exhibited an absolute (100%) drug resis-
tance rate to erythromycin, tetracycline and clarithromycin, while U. urealyticum was highly 
resistant to clarithromycin (94.6%), tetracycline (86.5%), ciprofloxacin (83.8%) and erythro-
mycin (83.8%). Despite being the most commonly used antibiotic in the treatment of non-
gonococcal genitourinary infections, doxycycline continues to be the most effective agent for 
U. urealyticum and M. hominis. Doxycycline and josamycin were the most potent antibiotics 
(80%) in mixed infections with both U. urealyticum and M. hominis. Based on its effectiveness, 
josamycin could prove to be an alternative treatment for U. urealyticum infections. Still, it is 
believed that it is a matter of time until both mycoplasmas will develop resistance to these 
new generation antibiotics because of cross-border interaction with resistant agents [62].
Despite the evidence, physicians routinely favor macrolide antibiotics, for example, erythro-
mycin when treating Ureaplasma infections in premature neonates [64].
Antibiotic resistance determination of Ureaplasma spp. usually requires predetermination of 
bacterial titer, followed by antibiotic interrogation using a set bacterial input. A method for 
determining precise MICs and one for screening against multiple antibiotics using breakpoint 
thresholds were detailed in another study [65] enabling a concurrent determination of the 
bacterial load in a sample simultaneously with the determination of resistance without prior 
knowledge of bacterial load. Further PCR and sequence analyses were performed to deter-
mine the resistance mechanism upon ureaplasmas grown in commercially available selective 
medium. An adapted breakpoint analysis was employed to screen for the presence of resis-
tant mutants within the 61 isolates. Confirmation of Ureaplasma was determined by amplifica-
tion of the Ureaplasma-specific urease gene (a 430-bp DNA product).
A reliable method to determine antimicrobial susceptibility of Ureaplasma isolates without 
prior knowledge of inoculum size was developed when mutations in bacterial genes pre-
viously associated with resistance were investigated for isolates resistant to erythromycin 
and ciprofloxacin [66]. DNA encoding bacterial 23S rRNA gene, L22 and L4 proteins were 
amplified and sequenced for macrolide-resistant strains. Gyrase subunits and topoisomerase 
subunits were sequenced for ciprofloxacin-resistant strains, while tetM genes from both tet-
racycline-susceptible and tetracycline-resistant isolates were also sequenced. More erythro-
mycin-resistant studies are required to determine the prevalence of mutations in the relevant 
genes associated with resistance.
4. Conclusions
Discovery of antibiotic resistant strains is an important step in choosing the appropriate treat-
ment against bacterial STD after the positive detection of the causative agents. A proper treat-
ment can prevent the spreading of these diseases in the general population. Antimicrobial 
susceptibility testing proves to be useful in cases when bacteria can be isolated.
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The antibiotic resistance of C. trachomatis has significantly different characteristics from those 
of other bacteria. First, because chlamydiae are intracellular pathogens, antimicrobial suscep-
tibility must be determined by their ability to proliferate within a host cell in the presence of 
variable antibiotic concentrations. Second, in contrast to most bacteria, C. trachomatis displays 
a “heterotypic resistance” in vitro, the chlamydial population containing both susceptible and 
resistant organisms, only a small proportion of them exerting resistance at any given time [17].
The study of the Chlamydiae biology is complicated by their intracellular development, but 
knowledge of the recombination mechanism(s) may enable effective genetic manipulations.
Antimicrobial resistance of microorganisms is a quite dynamic phenomenon, highlighting the 
need for current prevalence and susceptibility data from various different institutions or geo-
graphic areas. The ability to use molecular assays for STD antimicrobial resistance surveillance 
would offer a significant advantage to public health programs and selected patient management.
Drug therapies can result in strains containing mutations that confer the highest resistance 
becoming prevalent. In contrast, rRNA mutations in laboratory strains are intentionally cre-
ated in order to evaluate drug interaction mechanisms. The creation of phenotypes with less 
effective resistance is possible only under controlled laboratory conditions.
The routine use of genomics in clinical settings is becoming a reality. For STDs, understand-
ing the diversity of the circulating strains and their changing over time pattern is a primary 
requirement. Comparative genomic studies on chlamydia have demonstrated that it under-
goes extensive recombination. Genome projects can also help us understand the phenomenon 
of antibiotic resistance in STD agents, particularly in the cases of C. trachomatis, where very 
little was known about the genetics of these organisms because of a lack of molecular tools 
and the inability to grow them outside cell cultures or host organisms [14].
In recent year, genomics was asked to clarify a number of clinical aspects. Although genome 
analysis of bacterial STD was not a main issue, it can undoubtedly reveal previously inacces-
sible aspects of pathogen biology, including changes that lead to antibiotic resistance thereof. 
Genetic methods enable the DNA extraction from different biological samples, and both the 
presence of the bacteria and its resistance to one or more antibiotics can be determined from a 
single DNA sample. By studying the genes that induce antibiotic resistance and the plasmids 
that transfer such genes the mechanism that leads to antibiotic resistance can be elucidated.
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